{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:25:46Z","timestamp":1747157146373,"version":"3.40.5"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.cellimm.2024.104827","type":"journal-article","created":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T03:05:03Z","timestamp":1715396703000},"page":"104827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Enhancing antitumor response by efficiently generating large-scale TCR-T cells targeting a single epitope across multiple cancer antigens"],"prefix":"10.1016","volume":"399-400","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7321-9121","authenticated-orcid":false,"given":"Obed Boadi","family":"Amissah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Basnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenfang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean de Dieu","family":"Habimana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda Edwina","family":"Baiden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osei Asibey","family":"Owusu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babangida Jabir","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cellimm.2024.104827_b0005","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2024.104827_b0010","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.coi.2018.04.007","article-title":"Adoptive T cell therapy: points to consider","volume":"51","author":"Yee","year":"2018","journal-title":"Curr. Opin. Immunol."},{"issue":"4","key":"10.1016\/j.cellimm.2024.104827_b0015","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3748\/wjg.v30.i4.286","article-title":"Revolutionizing gastric cancer treatment: The potential of immunotherapy","volume":"30","author":"Christodoulidis","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cellimm.2024.104827_b0020","doi-asserted-by":"crossref","DOI":"10.2217\/imt-2023-0230","article-title":"Immune checkpoint inhibitors in follicular dendritic cell sarcoma","author":"Assi","year":"2024","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.cellimm.2024.104827_b0025","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.cpt.2022.12.002","article-title":"Role of T cells in cancer immunotherapy: Opportunities and challenges","volume":"1","author":"Ahmed","year":"2023","journal-title":"Cancer Pathog. Ther."},{"issue":"8","key":"10.1016\/j.cellimm.2024.104827_b0030","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrclinonc.2011.100","article-title":"Immunotherapy: novel approach for universal adoptive cell transfer therapy with improved outcome","volume":"8","author":"Hutchinson","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"92","key":"10.1016\/j.cellimm.2024.104827_b0035","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adg7995","article-title":"Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8(+) T-myeloid cell networks in melanoma","volume":"9","author":"Barras","year":"2024","journal-title":"Sci. Immunol."},{"issue":"6","key":"10.1016\/j.cellimm.2024.104827_b0040","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1073\/pnas.1315606111","article-title":"CD28 and CD3 have complementary roles in T-cell traction forces","volume":"111","author":"Bashour","year":"2014","journal-title":"PNAS"},{"issue":"4","key":"10.1016\/j.cellimm.2024.104827_b0045","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00262-012-1384-4","article-title":"Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors","volume":"62","author":"McCormack","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.cellimm.2024.104827_b0050","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12935-024-03249-w","article-title":"NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route","volume":"24","author":"Amissah","year":"2024","journal-title":"Cancer Cell Int."},{"issue":"3","key":"10.1016\/j.cellimm.2024.104827_b0055","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2217\/imt-2023-0256","article-title":"A trispecific antibody induces potent tumor-directed T-cell activation and antitumor activity by CD3\/CD28 co-engagement","volume":"16","author":"Chen","year":"2024","journal-title":"Immunotherapy"},{"issue":"7","key":"10.1016\/j.cellimm.2024.104827_b0060","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/eji.1830210731","article-title":"T cell receptor\/CD3 and CD28 use distinct intracellular signaling pathways","volume":"21","author":"Van Lier","year":"1991","journal-title":"Eur. J. Immunol."},{"issue":"11","key":"10.1016\/j.cellimm.2024.104827_b0065","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00109-023-02374-9","article-title":"Large extracellular vesicles derived from human regulatory macrophages (L-EV(Mreg)) attenuate CD3\/CD28-induced T-cell activation in vitro","volume":"101","author":"Albrecht","year":"2023","journal-title":"J. Mol. Med. (Berl)"},{"issue":"5","key":"10.1016\/j.cellimm.2024.104827_b0070","doi-asserted-by":"crossref","first-page":"821","DOI":"10.17219\/acem\/35771","article-title":"The effects of anti-CD3\/CD28 coated beads and IL-2 on expanded T cell for immunotherapy","volume":"25","author":"Martkamchan","year":"2016","journal-title":"Adv. Clin. Exp. Med."},{"issue":"2","key":"10.1016\/j.cellimm.2024.104827_b0075","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.blre.2011.11.002","article-title":"Ex-vivo expansion of red blood cells: how real for transfusion in humans?","volume":"26","author":"Migliaccio","year":"2012","journal-title":"Blood Rev."},{"issue":"1","key":"10.1016\/j.cellimm.2024.104827_b0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13287-017-0761-5","article-title":"Establishment of xenogeneic serum-free culture methods for handling human dental pulp stem cells using clinically oriented in-vitro and in-vivo conditions","volume":"9","author":"Mochizuki","year":"2018","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.cellimm.2024.104827_b0085","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/123030","article-title":"Ex vivo expansion of human mesenchymal stem cells in defined serum-free media","volume":"2012","author":"Jung","year":"2012","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.cellimm.2024.104827_b0090","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3389\/fbioe.2020.00307","article-title":"Successful use of human AB serum to support the expansion of adipose tissue-derived mesenchymal stem\/stromal cell in a microcarrier-based platform","volume":"8","author":"Moreira","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.cellimm.2024.104827_b0095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000448196","article-title":"Characterization of human AB serum for mesenchymal stromal cell expansion","volume":"44","author":"Dos Santos","year":"2017","journal-title":"Transfus. Med. Hemother."},{"issue":"1","key":"10.1016\/j.cellimm.2024.104827_b0100","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2014.31","article-title":"Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement","volume":"4","author":"Smith","year":"2015","journal-title":"Clin Transl Immunology"},{"issue":"1","key":"10.1016\/j.cellimm.2024.104827_b0105","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2023.5261","article-title":"Impact of serum-free media on the expansion and functionality of CD19.CAR T-cells","volume":"52","author":"Eberhardt","year":"2023","journal-title":"Int. J. Mol. Med."},{"issue":"18","key":"10.1016\/j.cellimm.2024.104827_b0110","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-06-791202","article-title":"Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS","volume":"130","author":"Tawara","year":"2017","journal-title":"Blood"},{"issue":"7661","key":"10.1016\/j.cellimm.2024.104827_b0115","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nature22383","article-title":"Quantifiable predictive features define epitope-specific T cell receptor repertoires","volume":"547","author":"Dash","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2024.104827_b0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1275304","article-title":"Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC enables targeting of WT1-pMHC low expressing cancer cells by anti-WT1-pMHC\/CD3 T cell engagers","volume":"14","author":"Walseng","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2024.104827_b0125","doi-asserted-by":"crossref","first-page":"1114770","DOI":"10.3389\/fimmu.2023.1114770","article-title":"TCR T cells overexpressing c-Jun have better functionality with improved tumor infiltration and persistence in hepatocellular carcinoma","volume":"14","author":"Hussein","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2024.104827_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jare.2024.01.014","article-title":"The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer","author":"Tang","year":"2024","journal-title":"J. Adv. Res."},{"issue":"1","key":"10.1016\/j.cellimm.2024.104827_b0135","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41577-019-0203-y","article-title":"Metabolic coordination of T cell quiescence and activation","volume":"20","author":"Chapman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.cellimm.2024.104827_b0140","doi-asserted-by":"crossref","first-page":"e12956","DOI":"10.1111\/sji.12956","article-title":"Cellular metabolism dictates T cell effector function in health and disease","volume":"92","author":"Kolan","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.cellimm.2024.104827_b0145","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev.immunol.20.100101.151926","article-title":"T cell memory","volume":"20","author":"Sprent","year":"2002","journal-title":"Annu. Rev. Immunol."},{"issue":"18","key":"10.1016\/j.cellimm.2024.104827_b0150","first-page":"6076","article-title":"NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer","volume":"63","author":"Odunsi","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2024.104827_b0155","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.semcancer.2021.04.016","article-title":"Cancer\/testis antigens: from serology to mRNA cancer vaccine","volume":"76","author":"Fan","year":"2021","journal-title":"Semin. Cancer Biol."},{"issue":"12","key":"10.1016\/j.cellimm.2024.104827_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083212","article-title":"Centrosomal localisation of the cancer\/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cells","volume":"8","author":"Pagotto","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cellimm.2024.104827_b0165","first-page":"1","article-title":"Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy","volume":"11","author":"de Carvalho","year":"2011","journal-title":"Cancer Immun."},{"issue":"12","key":"10.1016\/j.cellimm.2024.104827_b0170","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1021\/acs.bioconjchem.0c00548","article-title":"Specific inhibition of tumor growth by T cell receptor-drug conjugates targeting intracellular cancer-testis antigen NY-ESO-1\/LAGE-1","volume":"31","author":"Qiu","year":"2020","journal-title":"Bioconjug. Chem."},{"issue":"2","key":"10.1016\/j.cellimm.2024.104827_b0175","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001748","article-title":"In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma","volume":"8","author":"Liu","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cellimm.2024.104827_b0180","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.omtm.2021.06.011","article-title":"Characterization and modulation of anti-alphabetaTCR antibodies and their respective binding sites at the betaTCR chain to enrich engineered T cells","volume":"22","author":"Kierkels","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"22","key":"10.1016\/j.cellimm.2024.104827_b0185","doi-asserted-by":"crossref","first-page":"10454","DOI":"10.1073\/pnas.90.22.10454","article-title":"A method for producing monoclonal antibodies to human T-cell-receptor beta-chain variable regions","volume":"90","author":"Callan","year":"1993","journal-title":"PNAS"},{"issue":"9","key":"10.1016\/j.cellimm.2024.104827_b0190","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1084\/jem.187.9.1529","article-title":"One of the CD3epsilon subunits within a T cell receptor complex lies in close proximity to the Cbeta FG loop","volume":"187","author":"Ghendler","year":"1998","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.cellimm.2024.104827_b0195","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.cellimm.2024.104827_b0200","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1002\/cpmb.125","article-title":"Optimized transgene delivery using third-generation lentiviruses","volume":"133","author":"Gill","year":"2020","journal-title":"Curr. Protoc. Mol. Biol."},{"issue":"12","key":"10.1016\/j.cellimm.2024.104827_b0205","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1016\/j.ymthe.2023.10.018","article-title":"Third-generation lentiviral gene therapy rescues function in a mouse model of Usher 1B","volume":"31","author":"Schott","year":"2023","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.cellimm.2024.104827_b0210","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s10616-013-9652-5","article-title":"Production, purification and titration of a lentivirus-based vector for gene delivery purposes","volume":"66","author":"Nasri","year":"2014","journal-title":"Cytotechnology"},{"issue":"1","key":"10.1016\/j.cellimm.2024.104827_b0215","article-title":"Generation of high-titer lentivirus for the production of transgenic quail","volume":"2009","author":"Poynter","year":"2009","journal-title":"Cold Spring Harb. Protoc."},{"issue":"8","key":"10.1016\/j.cellimm.2024.104827_b0220","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a036863","article-title":"New approaches on cancer immunotherapy","volume":"10","author":"Cha","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"8","key":"10.1016\/j.cellimm.2024.104827_b0225","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.cellimm.2024.104827_b0230","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun. Signal"},{"issue":"3","key":"10.1016\/j.cellimm.2024.104827_b0235","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3892\/ol.2024.14264","article-title":"Prognosis value of circulating tumor cell PD-L1 and baseline characteristics in patients with NSCLC treated with immune checkpoint inhibitors plus platinum-containing drugs","volume":"27","author":"Su","year":"2024","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.cellimm.2024.104827_b0240","doi-asserted-by":"crossref","DOI":"10.1038\/s43018-024-00730-3","article-title":"Clinical and translational attributes of immune-related adverse events","author":"Suijkerbuijk","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.cellimm.2024.104827_b0245","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1146\/annurev-med-062617-035821","article-title":"Redirected T cell cytotoxicity in cancer therapy","volume":"70","author":"Clynes","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.cellimm.2024.104827_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101437","article-title":"Adoptive T cell therapy: Boosting the immune system to fight cancer","volume":"49","author":"Leon","year":"2020","journal-title":"Semin. Immunol."},{"issue":"8","key":"10.1016\/j.cellimm.2024.104827_b0255","doi-asserted-by":"crossref","first-page":"e07686","DOI":"10.1016\/j.heliyon.2021.e07686","article-title":"Alternative to FBS in animal cell culture - An overview and future perspective","volume":"7","author":"Subbiahanadar Chelladurai","year":"2021","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.cellimm.2024.104827_b0260","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1038\/s41598-023-29060-7","article-title":"Fetal bovine serum, an important factor affecting the reproducibility of cell experiments","volume":"13","author":"Liu","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cellimm.2024.104827_b0265","doi-asserted-by":"crossref","first-page":"e20230020","DOI":"10.1590\/1678-7757-2023-0020","article-title":"Different concentrations of fetal bovine serum affect cytokine modulation in Lipopolysaccharide-activated apical papilla cells in vitro","volume":"31","author":"Santos","year":"2023","journal-title":"J. Appl. Oral Sci."},{"issue":"12","key":"10.1016\/j.cellimm.2024.104827_b0270","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s10529-019-02743-w","article-title":"Comparison of two commonly used methods for stimulating T cells","volume":"41","author":"Jiao","year":"2019","journal-title":"Biotechnol. Lett"},{"key":"10.1016\/j.cellimm.2024.104827_b0275","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1479-5876-8-104","article-title":"Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: differing impact on CD8 T cell phenotype and responsiveness to restimulation","volume":"8","author":"Li","year":"2010","journal-title":"J. Transl. Med."},{"issue":"16","key":"10.1016\/j.cellimm.2024.104827_b0280","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1016\/j.cell.2023.06.020","article-title":"Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy","volume":"186","author":"Dolton","year":"2023","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.cellimm.2024.104827_b0285","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.cell.2022.03.041","article-title":"Enhanced safety and efficacy of protease-regulated CAR-T cell receptors","volume":"185","author":"Labanieh","year":"2022","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.cellimm.2024.104827_b0290","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008566","article-title":"Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity","volume":"12","author":"Shabaneh","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.cellimm.2024.104827_b0295","doi-asserted-by":"crossref","first-page":"2035117","DOI":"10.1080\/21645515.2022.2035117","article-title":"Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders - Advances and challenges","volume":"18","author":"Goswami","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.cellimm.2024.104827_b0300","article-title":"The recent advancement of TCR-T cell therapies for cancer treatment","author":"Zhao","year":"2024","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874924000303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874924000303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T09:26:20Z","timestamp":1730107580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874924000303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":60,"alternative-id":["S0008874924000303"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2024.104827","relation":{},"ISSN":["0008-8749"],"issn-type":[{"type":"print","value":"0008-8749"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing antitumor response by efficiently generating large-scale TCR-T cells targeting a single epitope across multiple cancer antigens","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2024.104827","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104827"}}